-
EP1698339
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1698339
| EP1698339 - NEUTROPHILIA INHIBITOR [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 31.08.2012 Database last updated on 22.05.2024 | Most recent event Tooltip | 31.08.2012 | Application deemed to be withdrawn | published on 03.10.2012 [2012/40] | Applicant(s) | For all designated states Nissan Chemical Industries, Ltd. 7-1, Kanda Nishiki-cho 3-chome Chiyoda-ku Tokyo 101-0054 / JP | For all designated states TAISHO PHARMACEUTICAL CO., LTD 24-1 Takada 3-chome Toshima-ku Tokyo 170-8633 / JP | [2006/36] | Inventor(s) | 01 /
IWAMA, Takehisa, Nissan Chemical Industries Ltd Bio. Res. Lab.,1470, Oaza-shiraoka, Shiraoka-machi Minamisaitama-gun, Saitama 3490218 / JP | 02 /
TSURUZOE, Nobutomo, Nissan Chemical Industries Ltd Bio. Res. Lab.,1470, Oaza-shiraoka, Shiraoka-machi Minamisaitama-gun, Saitama 3490218 / JP | [2006/36] | Representative(s) | Blodig, Wolfgang Wächtershäuser & Hartz Patentanwaltspartnerschaft mbB Weinstrasse 8 80333 München / DE | [N/P] |
| Former [2006/36] | Blodig, Wolfgang Wächtershäuser & Hartz Patentanwälte Weinstrasse 8 80333 München / DE | Application number, filing date | 04807556.8 | 22.12.2004 | [2006/36] | WO2004JP19199 | Priority number, date | JP20030433747 | 26.12.2003 Original published format: JP 2003433747 | [2006/36] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2005063250 | Date: | 14.07.2005 | Language: | EN | [2005/28] | Type: | A1 Application with search report | No.: | EP1698339 | Date: | 06.09.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.07.2005 takes the place of the publication of the European patent application. | [2006/36] | Search report(s) | International search report - published on: | JP | 14.07.2005 | (Supplementary) European search report - dispatched on: | EP | 19.05.2009 | Classification | IPC: | A61K31/501, A61P7/00, A61P11/00, C07D401/12 | [2009/23] | CPC: |
C07D401/12 (EP,KR,US);
A61K31/501 (EP,KR,US);
A61P11/00 (EP);
A61P19/02 (EP);
A61P19/04 (EP);
A61P19/06 (EP);
A61P29/00 (EP);
A61P31/00 (EP);
A61P35/00 (EP);
|
| Former IPC [2006/36] | A61K31/501, A61P7/00, A61P11/00, // C07D401/12 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/36] | Extension states | AL | 07.06.2006 | BA | 07.06.2006 | HR | 07.06.2006 | LV | 07.06.2006 | MK | 07.06.2006 | YU | 07.06.2006 | Title | German: | NEUTROPHILIE-HEMMER | [2006/36] | English: | NEUTROPHILIA INHIBITOR | [2006/36] | French: | INHIBITEUR DE NEUTROPHILIE | [2006/36] | Entry into regional phase | 07.06.2006 | Translation filed | 07.06.2006 | National basic fee paid | 07.06.2006 | Search fee paid | 07.06.2006 | Designation fee(s) paid | 07.06.2006 | Examination fee paid | Examination procedure | 26.05.2005 | Request for preliminary examination filed International Preliminary Examining Authority: JP | 07.06.2006 | Examination requested [2006/36] | 28.07.2009 | Despatch of a communication from the examining division (Time limit: M06) | 09.12.2009 | Reply to a communication from the examining division | 01.12.2011 | Communication of intention to grant the patent | 12.04.2012 | Application deemed to be withdrawn, date of legal effect [2012/40] | 21.05.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2012/40] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.07.2009 | Fees paid | Renewal fee | 07.06.2006 | Renewal fee patent year 03 | 14.12.2007 | Renewal fee patent year 04 | 12.12.2008 | Renewal fee patent year 05 | 10.12.2009 | Renewal fee patent year 06 | 29.11.2010 | Renewal fee patent year 07 | 01.12.2011 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]EP0482208 (NISSAN CHEMICAL IND LTD [JP]) [X] 1-5 * See compounds of formula (I) in the claims and the specific examples in table 1 (page 23 ff) * * See page 4, line 33 and page 76, line 42-43 " asthma" and "allergic diseases" *; | [X]US5798357 (IKEGAWA RURIKO [JP], et al) [X] 1-5 * See compounds of formula (I), and in particular the compounds of claim 2 * * See column 1, line 20: "pulmonary disorders" and lines 35-45 "TXA2- mediated diseases". * * See column 3, line 13 and column 6, line 56: bronchial asthma" *; | [Y] - HORIGUCHI T ET AL, "Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, (20020101), vol. 52, no. 10, ISSN 0004-4172, pages 764 - 768, XP002998194 [Y] 1-5 * See the use of seratrodast, a TXA2 receptor antagonist, for the treatment of COPD * | [Y] - DAV G ET AL, "Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE DEC 1997, (199712), vol. 156, no. 6, ISSN 1073-449X, pages 1794 - 1799, XP002525439 [Y] 1-5 * See abstract, results and discussion: thromboxane biosynthesis is enhanced in COPD * | [Y] - BASILI S ET AL, "Potential usefulness of antiplatelet agents in patients with chronic obstructive pulmonary disease", THROMBOSIS RESEARCH, TARRYTOWN, NY, US, (19961115), vol. 84, no. 4, ISSN 0049-3848, pages 279 - 284, XP002382386 [Y] 1-5 * See abstract: use of antiplatelet agents for the treatment of COPD * DOI: http://dx.doi.org/10.1016/S0049-3848(96)00187-9 | International search | [Y]WO0033845 (NISSAN CHEMICAL IND LTD [JP], et al); | [Y] - ELWOOD W. ET AL., "Inhibition of allegren-induced lungeosinophila by type-III and combined type-II and IV-selective phosphodiesterase inhibitors in Brown-Noeway rats", INFLAMM. RES., (1995), vol. 44, pages 83 - 86, XP008112791 DOI: http://dx.doi.org/10.1007/BF01793218 | Examination | - QUINT JENNIFER KATHLEEN ET AL, The neutrophil in chronic obstructive pulmonary disease., THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY MAY 2007 LNKD- PUBMED:17270263, VOL. 119, NR. 5, PAGE(S) 1065 - 1071, (200705), ISSN 0091-6749 |